JP2014502961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502961A5 JP2014502961A5 JP2013543601A JP2013543601A JP2014502961A5 JP 2014502961 A5 JP2014502961 A5 JP 2014502961A5 JP 2013543601 A JP2013543601 A JP 2013543601A JP 2013543601 A JP2013543601 A JP 2013543601A JP 2014502961 A5 JP2014502961 A5 JP 2014502961A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- peptide
- peptides
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 239000003098 androgen Substances 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 239000003970 toll like receptor agonist Substances 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2010/069675 | 2010-12-14 | ||
| PCT/EP2010/069675 WO2011073215A2 (en) | 2009-12-14 | 2010-12-14 | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| PCT/EP2011/070024 WO2012079878A2 (en) | 2010-12-14 | 2011-11-14 | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502961A JP2014502961A (ja) | 2014-02-06 |
| JP2014502961A5 true JP2014502961A5 (https=) | 2014-12-25 |
| JP6032853B2 JP6032853B2 (ja) | 2016-11-30 |
Family
ID=44983532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543601A Expired - Fee Related JP6032853B2 (ja) | 2010-12-14 | 2011-11-14 | 前立腺関連抗原分子由来ｈｌａ結合ペプチドおよびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JP6032853B2 (https=) |
| KR (1) | KR20130126671A (https=) |
| CN (1) | CN103547283A (https=) |
| AU (1) | AU2011344652B2 (https=) |
| CA (1) | CA2821582A1 (https=) |
| MX (1) | MX2013006758A (https=) |
| NZ (1) | NZ609916A (https=) |
| SG (1) | SG191154A1 (https=) |
| WO (1) | WO2012079878A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013012432A1 (de) * | 2013-07-29 | 2015-01-29 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immuntherapie von Prostatakrebs |
| RU2689145C2 (ru) * | 2014-04-16 | 2019-05-24 | Биокон Лтд. | Стабильные белковые препараты, содержащие молярный избыток сорбитола |
| US10639329B2 (en) * | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| WO2018148671A1 (en) * | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
| KR102215578B1 (ko) * | 2019-03-28 | 2021-02-15 | 한국과학기술연구원 | 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA725596A (en) | 1960-08-26 | 1966-01-11 | J. Wretlind Arvid | Method of preparing intravenously injectable fat emulsions free from side reactions or complications |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| CA2394741A1 (en) * | 1999-12-21 | 2001-06-28 | Epimmune Inc. | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US20020081680A1 (en) * | 2000-04-17 | 2002-06-27 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| WO2003070889A2 (en) * | 2002-02-19 | 2003-08-28 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
| AU2003256912A1 (en) * | 2002-08-16 | 2004-03-03 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| AU2003302820A1 (en) * | 2002-12-05 | 2004-06-30 | Diadexus, Inc. | Compositions, splice variants and methods relating to breast specific genes and proteins |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| WO2006023598A2 (en) * | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| PL1642905T3 (pl) | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| PT2113253E (pt) * | 2008-04-30 | 2010-06-15 | Immatics Biotechnologies Gmbh | Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas |
| SI2119726T2 (en) * | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
-
2011
- 2011-11-14 WO PCT/EP2011/070024 patent/WO2012079878A2/en not_active Ceased
- 2011-11-14 CN CN201180059274.2A patent/CN103547283A/zh active Pending
- 2011-11-14 NZ NZ60991611A patent/NZ609916A/en not_active IP Right Cessation
- 2011-11-14 MX MX2013006758A patent/MX2013006758A/es unknown
- 2011-11-14 JP JP2013543601A patent/JP6032853B2/ja not_active Expired - Fee Related
- 2011-11-14 KR KR1020137018147A patent/KR20130126671A/ko not_active Withdrawn
- 2011-11-14 AU AU2011344652A patent/AU2011344652B2/en not_active Ceased
- 2011-11-14 SG SG2013045737A patent/SG191154A1/en unknown
- 2011-11-14 CA CA2821582A patent/CA2821582A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502961A5 (https=) | ||
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| CL2020001897A1 (es) | Tratamientos contra el cáncer de útero. (divisional solicitud 201802508) | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| EA201892021A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| EA201891759A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| JP2018509935A5 (https=) | ||
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| JP2018510215A5 (https=) | ||
| EP2562183A8 (en) | Novel immunogenic epitopes for immunotherapy | |
| CA3033115A1 (en) | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
| NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
| EP2528937A4 (en) | MODIFIED MELK-PEPTIDES AND VACCINES CONTAINING THEREOF | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| EP3556857A3 (en) | Cdc45l peptides and vaccines including the same | |
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| MX2020011787A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| MY170949A (en) | A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine | |
| NZ593200A (en) | Peptide adjuvants | |
| MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
| BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos |